XML 20 R4.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Total revenue $ 145.2 $ 186.3
Costs and expenses:    
Research and development expense 17.6 21.3
Change in the fair value of contingent consideration (1.1) 0.7
Selling, general, and administrative expense 124.1 135.5
Total costs and expenses 184.8 207.2
Operating loss (39.6) (20.9)
Other income (expense):    
Interest income 0.4 0.9
Interest expense (2.9) (2.9)
Other (1.6) 0.6
Total other expense, net (4.1) (1.4)
Loss before income tax (43.7) (22.3)
Income tax benefit (28.5) (1.7)
Net loss (15.2) (20.6)
Net loss attributable to non-controlling interest 0.0 0.0
Net loss attributable to Myriad Genetics, Inc. stockholders $ (15.2) $ (20.6)
Net loss per share:    
Basic and diluted (in dollars per share) $ (0.20) $ (0.28)
Weighted average shares outstanding:    
Basic and diluted (shares) 74.7 73.7
Molecular diagnostic testing    
Total revenue $ 135.7 $ 172.0
Costs and expenses:    
Costs and expenses 39.9 41.2
Pharmaceutical and clinical services    
Total revenue 9.5 14.3
Costs and expenses:    
Costs and expenses $ 4.3 $ 8.5